

## Appendix C: Acronyms (Last updated October 26, 2016; last reviewed October 26, 2016)

<b>Acronym/Abbreviation</b>	<b>Full Name</b>
3TC	lamivudine
ABC	abacavir
ACOG	American College of Obstetricians and Gynecologists
ALT	alanine aminotransferase
anti-HBc	anti-hepatitis B core antibody
anti-HBS	hepatitis B surface antibody
AOR	adjusted odds ratio
AP	anteartum
ART	antiretroviral therapy
ARV	antiretroviral
AST	aspartate aminotransferase
ATV	atazanavir
ATV/r	atazanavir/ritonavir
AUC	area under the curve
AZT	zidovudine
BID	twice daily
BMI	body mass index
CBC	complete blood count
CD4	CD4 T lymphocyte
CDC	Centers for Disease Control and Prevention
CI	confidence interval
C <sub>max</sub>	maximum plasma concentration
C <sub>min</sub>	minimum plasma concentration
CNS	central nervous system
COBI	cobicistat
CVS	chorionic villus sampling
CYP	cytochrome P
CYP3A4	cytochrome P450 3A4
d4T	stavudine
ddI	didanosine
DMPA	depot medroxyprogesterone acetate
DRV	darunavir
DRV/r	darunavir/ritonavir
DSMB	Data and Safety Monitoring Board

DTG	dolutegravir
EC	enteric coated
ECG	electrocardiogram
EFV	efavirenz
EMS	ethyl methane sulfonate
ETR	etravirine
EVG	elvitegravir
FDA	Food and Drug Administration
FDC	fixed drug combination
FPV	fosamprenavir
FPV/r	fosamprenavir/ritonavir
FTC	emtricitabine
gp	glycoprotein
HAV	hepatitis A virus
HBIG	hepatitis B immune globulin
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus
HELLP	hemolysis, elevated liver enzymes, and low platelets
HGC	hard gel capsule
HR	hazard ratio
HRSA	Health Resources and Services Administration
HSR	hypersensitivity reaction
IC <sub>50</sub>	inhibitory concentration 50%
IDV	indinavir
IDV/r	indinavir/ritonavir
IGF	insulin-like growth factor
IgG	Immunoglobulin G
IP	intrapartum
IQR	interquartile range
IRIS	immune reconstitution inflammatory syndrome
IUD	intrauterine device
IV	intravenous/intravenously
LPV	lopinavir
LPV/r	lopinavir/ritonavir
MAC	<i>Mycobacterium avium</i> complex
mtDNA	mitochondrial DNA
MVC	maraviroc

NFV	nelfinavir
NIH	National Institutes of Health
NNRTI	non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor
NtRTI	nucleotide analogue reverse transcriptase inhibitor
NVP	nevirapine
OC	oral contraceptive
OI	opportunistic infection
OR	odds ratio
The Panel	The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission
PCP	<i>Pneumocystis jirovecii</i> pneumonia
PCR	polymerase chain reaction
PI	protease inhibitor
PK	pharmacokinetic
PO	orally
PP	postpartum
PPI	proton pump inhibitor
PrEP	pre-exposure prophylaxis
PTD	preterm delivery
RAL	raltegravir
RDS	respiratory distress syndrome
RPV	rilpivirine
RR	relative risk
RTV	ritonavir
SD	single dose
SQ	subcutaneous
SQV	saquinavir
SQV/r	saquinavir/ritonavir
STD	sexually transmitted disease
T20	enfuvirtide
TAF	tenofovir alafenamide
TDF	tenofovir disoproxil fumarate
TDM	therapeutic drug monitoring
TID	three times daily
TPV	tipranavir
TPV/r	tipranavir/ritonavir

UGT	uridine diphosphate glucuronosyltransferase
WHO	World Health Organization
ZDV	zidovudine